1 6
У к р а ї н с ь к и й р е в м а т о л о г і ч н и й ж У р н а л • № 3 ( 8 5 ) • 2 0 2 1
ment of Fulminant Myocarditis: A Scientific Statement From the Ameri-
can Heart Association. Circulation, Vol. 141(6): e69–e92. doi: 10.1161/
CIR.0000000000000745.
44.
Kovalenko V., Nesukay E., Cherniuk S. et al.
(2020) Role
of myocardial inflammation and fibrosis in
the development of ventricu-
lar arrythmias in patients with inflammatory cardiomyopathy (results of
1-year follow-up). Eur. Heart J., Vol. 41 (Suppl. 2). ESC Congress. Ab-
stract Supplement: 2054. doi.org/10.1093/ehjci/ehaa946.2054.
45.
Krejci J., Mlejnek D., Sochorova D. et al.
(2016) In-
flammatory cardiomyopathy: a current view on pathophysiology, di-
agnosis and treatment. BioMed Research International: 1–11. doi:
10.1155/2016/4087632.
46.
Kuhl U., Lassner D., Gast M. et al.
(2015) Differential car-
diac microRNA expression predicts the clinical
course in human entero-
virus cardiomyopathy. Circ. Heart Fail, Vol. 8: 605–618. doi: 10.1161/
CIRCHEARTFAILURE.114.001475.
47.
Kuruvilla S., Adenaw N., Katwal A.B. et al.
(2014) Late
gadoli nium enhancement on cardiac magnetic resonance predicts adverse
cardiovascular outcomes in nonischemic cardiomyopathy:
a systema tic
review and meta-analysis. Circ. Cardiovasc. Imaging, Vol. 7(2): 250–
258. doi: 10.1161/CIRCIMAGING.113.001144.
48.
Leone O., Pieroni M., Rapezzi C. et al.
(2019) The spectrum
of myocarditis: from pathology to the clinics. Virchows Arch., Vol. 475(3):
279–301. doi: 10.1007/s00428–019–02615–8.
49.
Достарыңызбен бөлісу: 
